NovelStem International Corp.
0.0200+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · NSTM · USD
Key Stats
Market Cap
937.63KP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
NovelStem swung to a net profit of $2.5M for the six months ended June 30, 2025, up from a $0.6M loss last year, driven by $1.7M relief of indebtedness from settling a $3.0M litigation funding liability via the noncash sale of its 50% NetCo stake on May 9, 2025, plus a $1.2M gain on that disposal; Q2 alone delivered $2.8M income versus a $0.3M loss prior year. Operating losses narrowed to $0.2M from $0.3M y/y, with G&A expenses dropping 52% to $159K on lower legal and audit costs, while interest expense fell 19% to $164K after the settlement. Cash dipped to $1.1K amid $110K operating burn, offset by $106K in related-party bridge loans; total debt stands at $1.6M, mostly short-term notes at 10-12% maturing late 2025. Diluted EPS of $0.05 reconciles cleanly to 47.8M shares. Yet liquidity strains persist.
10-Q
Q1 FY2025 results
NovelStem International Corp. posted a narrower net loss of $207,216 for Q1 2025 ended March 31, versus $303,280 a year earlier, as administrative fee income dried up to zero from $3,000 while G&A expenses dropped 48% to $94,574 on lower professional fees. Operating loss improved to $(94,574) from $(180,306), but interest expense climbed 19% to $112,642 amid rising debt; net loss exceeded operating by $113,068, mainly from interest. Cash dwindled to $3,401 from $6,099, with operating cash use at $43,698 offset by $41,000 in bridge financing from the executive chairman. Total debt hit $4,601,611 including accrued interest, all current with no revolver. Post-quarter, on May 9, 2025, the company sold its 50% NetCo stake for $1,300,000 to settle a $3,000,000 litigation funding liability in full. Non-GAAP metrics not disclosed in the 10-Q. Yet liquidity strains persist.
10-K
FY2024 results
NovelStem International Corp. narrowed its net loss to $3.2 million in FY2024 from $4.2 million the prior year, driven by a sharp drop in litigation expenses to $59,000 from $2.9 million as the NetCo arbitration wrapped up, though an impairment charge wiped out its $1.6 million investment in NewStem after the biotech unit ceased operations in Q4 and entered liquidation. Administrative fee income held steady at $12,000 annually, while G&A costs rose 32% to $881,000 amid bad debt write-offs on $500,000 in NewStem loans and higher professional fees. Q4 momentum stalled with NewStem's shutdown, but the company advanced $250,000 in Q4 loans that proved uncollectible, underscoring liquidity strains with cash dipping to $6,000 from $53,000. Debt ballooned to $5.3 million, including $4.1 million in notes with related parties, yet a pending NetCo sale for $1.3 million could settle litigation funding obligations. No dividends or buybacks occurred. Illiquid holdings in NetCo and NewStem's reverted tech pose ongoing risks to quarterly cash flows.
10-Q
Q3 FY2024 results
NovelStem International Corp. posted a net loss of $3.1M for the nine months ended September 30, 2024, improved from $4.2M a year earlier, driven by the absence of prior-year litigation costs yet offset by a $1.6M impairment on its NewStem investment amid the biotech's liquidation. Administrative fee income held steady at $9,000 year-over-year, while G&A expenses climbed 40.7% to $894K, fueled by a $500K bad debt write-off on NewStem advances; operating loss narrowed to $885K from $3.4M. Q3 alone saw a $2.5M net loss, up from $1.1M last year, with EPS at $(0.05) on 46.9M diluted shares, consistent across periods. Cash dipped to $45K from $53K at year-start, with $233K used in operations and $475K raised via related-party notes and convertible debt; total debt stood at $4.1M, including a $2.9M litigation funding liability due January 2025. No free cash flow disclosed in the 10-Q. The arbitration win affirmed rights to exploit NetCo's Net Force IP, but joint venture control remains contested.
10-Q
Q2 FY2024 results
NovelStem International Corp. narrowed its net loss to $606K for the six months ended June 30, 2024, from $3.1M a year earlier, thanks to $6K in administrative fee income and the absence of $2.3M litigation expenses that hammered last year; the operating loss shrank to $321K from $2.9M, while equity in net losses from investees like NewStem and NetCo eased to $108K from $177K. Q/Q, the three-month net loss held steady at $303K, with G&A expenses dropping to $144K from $386K. Cash dipped to $7.9K amid $170K used in operations, offset by $375K in financing from notes and convertible debt, leaving total debt around $3.8M including a $2.9M litigation funding liability due January 2025. A planned acquisition of remaining NewStem shares fell through in July 2024 over funding shortfalls, triggering breach notices. Yet liquidity strains persist. Ongoing arbitration setbacks limit NetCo's IP exploitation.
ACUT
Accustem Sciences Inc.
1.24+0.00
BSEM
BioStem Technologies, Inc.
4.66+0.16
CHEK
Check-Cap Ltd.
1.45-0.04
ISCO
International Stem Cell Corp.
0.15+0.00
NEO
NeoGenomics, Inc.
10.28+0.36
NGHI
New Green Hemp Inc.
0.40+0.00
NOTV
Inotiv, Inc.
1.33-0.01
NVCR
NovoCure Limited
13.48+0.11
RMTG
Regenerative Medical Technology
0.05+0.00
STEK
Stemtech Corp.
0.00-0.00